基于文献计量学和可视化技术的抗栓治疗危险因素分析

Analysis of Risk Factors for Antithrombotic Therapy Based on Bibliometrics and Visualization Techniques

目的分析国内外抗栓治疗(抗血小板治疗和抗凝治疗,即抗栓的药物治疗)危险因素的现状和特点,为防治抗栓治疗引起的血栓或出血提供理论依据。方法检索2011年1月至2021年11月期间发表在中文数据库(中国期刊全文数据、万方数据库、维普数据库)以及英文数据库(PubMed、Web of science、MEDLINE)有关抗栓治疗危险因素的相关文献,进行文献计量学分析并使用VOSviewer软件进行可视化分析。结果共纳入595篇文献,英文文献发表量前三的国家分别为美国、中国和日本。研究类型以队列研究为主,样本数量大多在1000例以内。抗栓治疗危险因素分为影响抗血小板药物、华法林以及新型口服抗凝药治疗的危险因素。年龄、性别、肾功能、抗栓药物的联用等是共同的危险因素,不同的抗栓药物的危险因素也有其自身特点。结论国内外抗栓治疗危险因素的研究数量较多但样本量有待增加。药师应基于不同药物和不同人群进行个体化用药服务,保障患者的用药安全。

Objective To analyze the current situation and characteristics of risk factors in antithrombotic therapy(including antiplatelet and anticoagulant treatments)at home and abroad,and to provide a theoretical basis for the prevention and treatment of thrombosis or bleeding associated with antithrombotic therapy.Methods The literature on risk factors of antithrombotic therapy published in Chinese databases(China Journal Full-text Data,Wanfang Database,VIP Database)and English databases(PubMed,Web of Science,MEDLINE)from January 2011 to November 2021 was searched and bibliometric analysis was performed.The visualization analysis was performed using VOS viewer software.Results A total of 595 publications were included in the analysis.The top three countries for English publications were the USA,China,and Japan.The type of studies were predominantly cohort studies,with sample sizes mostly being below 1000.Risk factors for antithrombotic therapy are categorized into those affecting antiplatelet drugs,warfarin,and new oral anticoagulants.Age,gender,renal function,and combination of antithrombotic drugs are common risk factors,and different risk factors of antithrombotic drugs also have their characteristics.Conclusion While there is substantial research on risk factors in antithrombotic therapy globally,the sample size needs to be improved.Pharmacists should provide individualized medication services based on different drugs and different groups to ensure medication safety for patients.